Phase Ib/II Trial of Histone Deacetylase Inhibitor CXD101 in Combination With Programmed Cell Death Protein-1 Inhibitor Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Pembrolizumab (Primary) ; Zabinostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms PLACARD
- 12 Aug 2021 Planned End Date changed from 1 Oct 2027 to 1 Apr 2025.
- 12 Aug 2021 Planned primary completion date changed from 1 Oct 2026 to 1 Apr 2024.
- 12 Aug 2021 Status changed from recruiting to withdrawn prior to enrolment.